Download Panel Discussion

Bayer‘s Drive for Sustainable Healthcare
Innovations in Asia
Prof. Dr. A. Busch
Member of the Bayer HealthCare Executive Committee
and Head of Global Drug Discovery
Bayer HealthCare
[email protected]
R&D Focus of Bayer Pharmaceuticals Addresses
Healthcare Challenges in Asia-Pacific
Oncology/ Gynecology
 Cell Cycle / Survival Signaling
 Immunotherapy / AntibodyDrug Conjugates
 Pulmonary Hypertension /
Heart Failure
 Thrombosis / Acute Coronary
Syndrome
 Tumor Metabolism /
Hypoxia
 Cardiorenal Syndrome (CRS)
 Chromatin Modulation /
OncoGenomics
 Anemia and other blood
diseases
 Endometriosis
 LCM long acting factor VIII
 Uterine Fibroids
Highly competitive internal platforms
 SMOLs (compound library and screening)
 Antibody-platform (including ADCs)
 DMPK, Tox, CMC
Page 2
Cardiology/ Hematology
Singapore, WHSRMA, April 2013
Prof. A. Busch, Bayer Pharma AG
Asian-prevalent Gastric, Liver and Lung Cancers
Present a Major Health Problem in the Region
Liver Cancer
World Regions
Stomach Cancer
World Regions
World Age-standardized incidence rates per 100,000 population
 Asia alone had the highest number of cancer deaths in the world with over 4 million
(54%) and over 6 million new cancer cases in 2008 1
 Cancer is the leading cause of death in Singapore, causing 30% of deaths in 2011 2
Original data sources: Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International
Agency for Research on Cancer,2010. Available from: http://globocan.iarc.fr
1 CancerStats:Cancer Worldwide (Sept 2011). WHO International Agency for Research on Cancer. Retrieved from http://publications.cancerresearchuk.org/downloads/Product/CS_CS_WORLD.pdf on 05/12/12
2 Ministry of Health Singapore. www.moh.gov.sg/content/moh_web/home/statistics/Health_Facts_Singapore/Principal_Causes_of_Death.html
Sorafenib - Fighting Liver Cancer, a Deadly
Disease with High Prevalence in Asia
 Liver cancer is the third leading cause of cancer-related deaths worldwide,
fifth most common cancer in men, and especially prevalent in Asia
 Hepatocellular Carcinoma (HCC) is the most common form of liver cancer
 Poor prognosis for patients with all histologies (5-year survival rate is only
~ 10% or less for non-resectable tumors)
Bayer´s Tyrosine Kinase Inhibitor Sorafenib is
The only approved systemic therapy for advanced liver cancer
The first oral targeted therapy to treat advanced kidney cancer
Comprehensive development program underway in thyroid and breast cancer
Page 4
Singapore, WHSRMA, April 2013
Prof. A. Busch, Bayer Pharma AG
Bayer´s Continuous Search for Cancer Solutions in Asia
* metastatic colorectal cancer and gastrointestinal stromal tumors
Page 5
Singapore, WHSRMA, April 2013
Prof. A. Busch, Bayer Pharma AG
Sustaining Innovation in Asia-Pacific by
Combining Bayer´s Competitive Platforms
with a Flexible Partnering Strategy
 Joint labs
 Strategic
partnerships
 Consortia
 Joint research
 Crowdsourcing
Integration
Co-location
Multiple
projects, close
interaction
Individual
project
Partner
 Outsourcing
Page 6
 Licensing
Transition
of assets
 Incubator
Arm‘s
length
Singapore, WHSRMA, April 2013
Prof. A. Busch, Bayer Pharma AG
Examples
 DKFZ
 OncoMed
Biotech companies
Type
Academic institutions
Within Bayer
 IMI
 China, Singapore
 Grants4Targets
 Ardea
 CoLaborator
Bayer´s Oncology Partnerships from Bench to Bedside
Richie Soong, Patrick Tan
Hung Huynh
Goh Boon Cher
- In vitro analyses of drug candidates
- Identification of stratification markers
- Mutation analysis in Asian population
- Xenograft models for in vivo
analysis of cancer drug candidates
- Paired biopsy study with
Regorafenib to assess
biomarkers in Colorectal Ca
-Gastric Cancer, HCC
-Gastric Cancer, HCC, NSCLC
Research
Target
Lead
Lead
discovery discovery optimization
Kishore Bhakoo
- Target discovery (tumor
metabolism, HCC),
imaging for translational
research
Pre-clinical
development
Goh Boon Cher,
Hsieh Wen-son
Clinical development
Phase I Phase II Phase III
Goh Boon Cher, Daniel Tan
- Clinical studies
In vitro and xenograft studies to
evaluate potential activity of Bayer
drug in Nasopharyngeal Ca
 Bayer Singapore integrated translational oncology network joins expertise
together to develop novel therapies for Asian cancer patients
Page 7
Singapore, WHSRMA, April 2013
Prof. A. Busch, Bayer Pharma AG
Bayer – Science for a Better Life

Bayer addresses the high unmet medical need of increasing burden of
disease in the Asia-Pacific region (Asian-prevalent cancers, eye diseases,
heart diseases and stroke) by bringing innovative therapies to the
patients

Bayer is strongly committed to Oncology with several late stage and
launched compounds in HCC, RCC, CRC, GIST and CRPC (Sorafenib,
Regorafenib and Radium-223) as well as a strong early clinical pipeline

Partnerships with regional and local institutions and academia as well as
increasing clinical trial activities are key components of Bayer
HealthCare’s sustainable R&D strategy in Asia-Pacific

Prime example of sustainable R&D efforts: Bayer-Singapore
Integrated Translational Oncology Network maximizes value of
expertise to address innovation needs for Asian cancer patients
Page 8
Singapore, WHSRMA, April 2013
Prof. A. Busch, Bayer Pharma AG
Page 9
Singapore, WHSRMA, April 2013
Prof. A. Busch, Bayer Pharma AG
Forward-Looking Statements
 This presentation may contain forward-looking statements based on
current assumptions and forecasts made by Bayer Group or
subgroup management.
 Various known and unknown risks, uncertainties and other factors
could lead to material differences between the actual future results,
financial situation, development or performance of the company and
the estimates given here. These factors include those discussed in
Bayer’s public reports which are available on the Bayer website at
www.bayer.com.
 The company assumes no liability whatsoever to update these
forward-looking statements or to conform them to future events or
developments.
Page 10
Singapore, WHSRMA, April 2013
Prof. A. Busch, Bayer Pharma AG
Healthcare Macro Trends in Asia-Pacific
Addressed by Bayer R&D Strategy
High unmet medical need
in various diseases
Asia-specific differences in
disease biology (e.g. cancer)
Need for
sustainable
healthcare
innovation
Growing and aging population
Demographic change
Page 11
Singapore, WHSRMA, April 2013
Increasing value demand and
requirements by patients
Prof. A. Busch, Bayer Pharma AG
Innovation Efforts in China Bayer-Tsinghua-Center BTC
 Joint Research Center for innovative drug discovery with University of Tsinghua
Culminated budget of US$ 1.000.000 per year (US$ 700 000 for joint projects)
 Governance
Director: Prof. Yigong Shi, Chairman: Prof L. Zhang, Vice Chairman: Prof. E. Ottow
Deputy director: Dr. J. Fanghaenel, Members: Prof. Y. Li, Prof. H. Wang, Prof. H. Wild, Dr. U. Nielsch, Dr. J. Hu
 22 joint research projects successfully initiated (e.g. in structure biology and
peptide chemistry)
 42 Bayer Investigator Awards granted to outstanding scientist from Tsinghua
University
 Prof. Dong as first Bayer chair holder nominated at Tsinghua University
 Promoting scientific exchange:
Bayer-Tsinghua Joint Symposium on Drug Discovery (2010, 2011, 2012)
Bayer Lectures, Tsinghua Bayer Summer School
Multiple visits of Tsinghua PI’s to research sites in Germany and the US
Page 12
Singapore, WHSRMA, April 2013
Prof. A. Busch, Bayer Pharma AG